Asset Details
Do you wish to reserve the book?
Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection
Do you wish to request the book?
Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection
2015
Overview
The efficacy of azithromycin vs. doxycycline for urogenital
Chlamydia trachomatis
infection was assessed in this randomized clinical trial. In a directly observed treatment context, the efficacy of azithromycin was 97% and that of doxycycline was 100%.
Urogenital
Chlamydia trachomatis
infection is the most prevalent bacterial sexually transmitted infection in the United States and worldwide.
1
,
2
Females are disproportionately affected by this infection because of the risk of pelvic inflammatory disease, which can lead to ectopic pregnancy and infertility. Efforts to prevent and control chlamydia infection, which have been aimed mainly toward the reduction of sequelae, have not diminished the high prevalence.
Along with screening, the provision of effective treatment is a cornerstone of chlamydia control programs. For the treatment of chlamydia infection, the Centers for Disease Control and Prevention (CDC) recommends oral administration of either 1 . . .
Publisher
Massachusetts Medical Society
Subject
/ Anti-Bacterial Agents - adverse effects
/ Anti-Bacterial Agents - therapeutic use
/ Azithromycin - adverse effects
/ Azithromycin - therapeutic use
/ Chlamydia Infections - drug therapy
/ Chlamydia trachomatis - isolation & purification
/ Doxycycline - therapeutic use
/ Failure
/ Female
/ Females
/ Humans
/ Male
/ Males
/ Prisons
/ Urine
